What is Growth Strategy and Future Prospects of Green Cross Company?

Launched in the US in September 2024, a key product has quickly secured inclusion in the formularies of major US health insurers and established contracts with three major pharmacy benefit management companies—CVS, UnitedHealth, and Cigna—along with eight specialty pharmacies, ensuring broad distribution across all 50 states. This initiative is projected to significantly contribute to revenue, with Q3 2024 sales in the US estimated at W30 billion on a standalone basis.

The company continues to strengthen its global footprint, actively working to increase its share in the global plasma-derived product market, particularly in South America. The immunoglobulin products market size in this region reached approximately USD 270 million in 2022. Since 2015, the company has been supplying products through government and private market bidding processes, and currently exports 12 plasma-derived products, including Albumin, to 32 countries worldwide.

Strategic mergers and acquisitions are central to the company's expansion. In December 2024, the company acquired the entire stake in ABO Holdings for $96.6 million, a move designed to secure a stable supply of raw materials for its blood products business in the United States. ABO Holdings operates six blood banks across three states, with two additional banks under construction expected to be operational by 2026, thereby completing vertical integration from raw material sourcing to production and sales.

The company signed a contract in November 2023 with Eubiologics for the Contract Manufacturing Organization (CMO) of an oral cholera vaccine, with an initial production volume set at 15 million doses until 2026. The company is also expanding its CMO business for cell and gene therapies, leveraging its state-of-the-art manufacturing facilities. Product pipeline advancements include MFDS approval for a recombinant anthrax vaccine in April 2025 and ongoing Phase 1 multinational clinical trials for a Sanfilippo syndrome type A (MPS IIIA) drug.

For the first quarter ended March 31, 2025, the company reported a net income of KRW 29,695.38 million, a substantial shift from a net loss of KRW 25,312.53 million in Q1 2024. Basic earnings per share from continuing operations also saw a positive change, moving from a loss of KRW 2,218 to KRW 2,602.

Fiscal year 2024 revenue reached KRW 1.68 trillion, a 3.3% increase from the previous year. While FY 2024 recorded a net loss of KRW 26.3 billion, this represented a 1.3% reduction in losses, with loss per share improving to KRW 2,303.

Mirae Asset Securities forecasts a strong rebound, projecting 2024 operating profit at W64 billion, an 85.8% year-over-year increase. Further growth is anticipated, with 2025 operating profit expected to reach W118.3 billion.

Revenue is projected to grow to W1.71 trillion in 2024, a 5.4% increase year-over-year. The company is expected to maintain an average annual revenue growth rate of 9.7% over the next two years.

GC Biopharma is enhancing supply chain security and cold chain integrity through real-time visibility technologies. This proactive approach aims to mitigate risks associated with theft, tampering, and cyberattacks.

The company is focused on establishing comprehensive Business Continuity Plans (BCP). These plans are designed to ensure operational resilience and preparedness for unforeseen disruptions, including those stemming from climate change.

GC Biopharma is actively adapting to evolving regulatory requirements, including new GMP guidelines for 2025 and emerging regulations for AI in drug discovery. This ensures continued compliance and operational integrity.

The company is monitoring and strategizing around policy shifts, such as the Inflation Reduction Act, to manage potential impacts on drug pricing and valuations. This includes navigating increased scrutiny on industry practices.